(HealthDay News) — Patients with chronic myeloid leukemia (CML) have a higher risk of albuminuria if they receive dasatinib rather than other tyrosine kinase inhibitors (TKIs), according to a study published in the Clinical Journal of the American Society of Nephrology.
Researchers examined glomerular injury through the urine albumin-creatinine ratio (UACR) in 82 patients with CML who were receiving TKI therapy for at least 90 days. There were 32 patients treated with dasatinib and 50 treated with other TKIs (31 on imatinib, 7 on bosutinib, 10 on nilotinib, and 2 on ponatinib).
The dasatinib-treated patients had significantly higher UACR levels than those treated with other TKIs (median, 28.0 mg/g and 15.0 mg/g, respectively).
Continue Reading
Fifty percent of dasatinib-treated patients and 30% of patients on other TKIs had moderate albuminuria. Of the patients who developed albuminuria, 19% in the dasatinib group and 0% in the other TKI group had severe albuminuria (UACR >300 mg/g).
The researchers also found that average steady-state concentrations of dasatinib were positively associated with UACR (P =.03).
“These findings warrant further prospective evaluation and updated guidelines for monitoring of this treatment’s emergent adverse event as well as preemptive approaches to mitigate the risk and potential consequences,” the researchers wrote.
Several researchers disclosed ties to the pharmaceutical and medical technology industries.
This article originally appeared on Cancer Therapy Advisor